Codexis and Bristol-Myers Extend Research Agreement
News Feb 01, 2006
Codexis also announced that it will receive an undisclosed milestone payment for having successfully achieved the program's research milestone.
The research agreement was announced May 24, 2005 and focused on improving biocatalyst productivity for an undisclosed product candidate in the Bristol-Myers Squibb pipeline using Codexis' proprietary MolecularBreeding™ directed evolution platform.
Under the extended term of the agreement Codexis will receive additional undisclosed research funding and an additional payment, at Bristol-Myers Squibb's option, upon delivery of an enzyme for pilot-scale testing at Bristol-Myers Squibb.
"We are delighted to announce the extension of the term of this agreement with BMS, one of the world's leading human therapeutics companies," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019